CJC-1295
Regulatory
Legal Status in 2026
Compounding restricted under the FDA 503A bulk-substance list.
Federal law restricts compounding of this compound. For compounds whose FDA-declared shortage has resolved, Section 503B bulk compounding rights have ended; Section 503A compounding remains possible only with a documented patient-specific clinical justification (a verified allergy to an inactive ingredient, or a strength the manufacturer does not make, not cost or convenience). For compounds affirmatively excluded by the FDA's Pharmacy Compounding Advisory Committee, compounding is not permitted under the bulk-substance list. The FDA-approved product (where one exists) is the appropriate default.
About
About CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.
Science
Mechanism of Action
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and secretion of growth hormone. The DAC modification allows binding to albumin in the bloodstream, significantly extending the half-life. Downstream effects include increased hepatic IGF-1 production, enhanced protein synthesis, lipolysis, and improved cellular repair mechanisms.
Dosing
Typical Protocol
CJC-1295 with DAC: 1–2 mg once or twice weekly subcutaneously. CJC-1295 without DAC (Modified GRF 1-29): 100–300 mcg before bed, combined with Ipamorelin 100–300 mcg. Most protocols run for 3–6 month cycles with periodic IGF-1 monitoring. Administered subcutaneously, typically before sleep to align with natural GH pulsation.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard: effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Providers advertising CJC-1295
A CJC-1295 mention is not a fulfillment check. Confirm with the provider exactly what is being dispensed and which pharmacy fills it.
Marek HealthMen's Health Telehealth · Peptide Therapy · LegitScript Certified
LifeForceMen's Health Telehealth · Peptide Therapy · LegitScript Certified
Olympia Pharmacy503A/503B Compounding Pharmacy · GLP-1 Specialist · PCAB & LegitScript
Belmar PharmacyCompounding Pharmacy · TRT & HRT · PCAB Accredited
NRG ClinicMen's Health Telehealth · GLP-1 Specialist
FagronCompounding Pharmacy
Defy MedicalMen's Health Telehealth · GLP-1 Specialist
Medical Health InstituteMen's Health Telehealth · Specialty Focused
TruForm LongevityClinic & Medical Practice · TRT & HRT
AlphaMan ClinicClinic & Medical Practice · GLP-1 Specialist
Performance Rejuvenation CenterClinic & Medical Practice · TRT & HRT
Hallandale HealthCompounding Pharmacy · PCAB Accredited
Compound comparisons
Compare CJC-1295
CJC-1295 set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.